Granules India Expects Pending U.S. FDA Approvals To Drive Profit Growth
An employee inspects a handful of tablets inside a pharmaceutical laboratories (Photographer: Martin Leissl/Bloomberg)

Granules India Expects Pending U.S. FDA Approvals To Drive Profit Growth

Granules India Ltd. plans to achieve 25 percent annualised profit growth for the next three years on the back of its pending U.S. Food and Drug Administration approvals and new launches.“We have ab...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.